[go: up one dir, main page]

PE20141282A1 - Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes - Google Patents

Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Info

Publication number
PE20141282A1
PE20141282A1 PE2014000506A PE2014000506A PE20141282A1 PE 20141282 A1 PE20141282 A1 PE 20141282A1 PE 2014000506 A PE2014000506 A PE 2014000506A PE 2014000506 A PE2014000506 A PE 2014000506A PE 20141282 A1 PE20141282 A1 PE 20141282A1
Authority
PE
Peru
Prior art keywords
carbamoil
ilo
tetrahydroisoquinoline
treatment
cr6r7
Prior art date
Application number
PE2014000506A
Other languages
English (en)
Inventor
Le Wang
George Doherty
Xilu Wang
Zhi-Fu Tao
Milan Brunko
Aaron Kunzer
Michael Wendt
Xiaohong Song
Robin Frey
Todd Hansen
Gerard Sullivan
Andrew Judd
Andrew Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20141282A1 publication Critical patent/PE20141282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 8-CARBAMOIL-2-(2,3-PIRID-6-ILO DISUSTITUIDO)-1,2,3,4-TETRAHIDROISOQUINOLINA DE FORMULA (I) DONDE X ES HETEROARILO OPCIONALMENTE SUSTITUIDO; Y1 ES FENILENO O HETEROARILENO(C5-C6) OPCIONALMENTE FUSIONADO A UNO O DOS ANILLOS; L1 ES (CR6R7)q, (CR6R7)s-O-(CR6R7)r, ENTRE OTROS, EN DONDE R6 Y R7 SON CADA UNO H, NH2, NHC(O)NH2, ENTRE OTROS; q ES DE 1 A 3; s Y r SON CADA UNO DE 0 A 3; Y2 ES CICLOALQUILO(C8-C14), HETEROCICLOALQUILO(C8-C14), ENTRE OTROS; Z1 ES HALOGENO, NO2, CN, ENTRE OTROS; R1 ES HALO, ALQUILO(C1-C6), ENTRE OTROS; R2 ES HALO, ALQUENILO(C2-C6), ENTRE OTROS; R3 ES HALO, ALQUILO(C1-C6), ALQUINILO(C2-C6), ENTRE OTROS; m ES DE 0 A 3; n ES DE 0 A 6; p ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: ACIDO 6-[8-(1,3-BENZOTIAZOL-2-ILCARBAMOIL)-3,4-DIHIDROISOQUINOLIN-2(1H)-IL]-3-{1-[TRICICLO[3.3.1.13,7]DEC-1-ILMETIL]-1H-PIRAZOL-4-IL}PIRIDIN-2-CARBOXILICO; ACIDO 6-[8-(1,3-BENZOTIAZOL-2-ILCARBAMOIL)-3,4-DIHIDROISOQUINOLIN-2(1H)-IL]-3-[3,5-DIMETIL-1-(TRICICLO [3.3.1.13,7]DEC-1-ILMETIL)-1H-PIRAZOL-4-IL]PIRIDIN-2-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE PROTEINAS ANTIAPOPTOTICAS Bcl-xL SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE VEJIGA, LEUCEMIA LINFOBLASTICA, MIELOMA
PE2014000506A 2011-10-14 2012-10-11 Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes PE20141282A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547162P 2011-10-14 2011-10-14
CN2012079012 2012-07-23

Publications (1)

Publication Number Publication Date
PE20141282A1 true PE20141282A1 (es) 2014-10-26

Family

ID=47116421

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000506A PE20141282A1 (es) 2011-10-14 2012-10-11 Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes

Country Status (36)

Country Link
EP (1) EP2766361B1 (es)
JP (2) JP6155270B2 (es)
KR (1) KR102019643B1 (es)
AR (1) AR088327A1 (es)
AU (2) AU2012322698A1 (es)
BR (1) BR112014009053B1 (es)
CA (1) CA2851364C (es)
CL (1) CL2014000905A1 (es)
CO (1) CO6950476A2 (es)
CR (2) CR20200097A (es)
CY (1) CY1118224T1 (es)
DK (1) DK2766361T3 (es)
DO (2) DOP2014000070A (es)
EC (1) ECSP14000357A (es)
ES (1) ES2598877T3 (es)
GT (1) GT201400064A (es)
HR (1) HRP20161319T1 (es)
HU (1) HUE030589T2 (es)
IL (1) IL231856A (es)
LT (1) LT2766361T (es)
ME (1) ME02514B (es)
MX (1) MX356031B (es)
MY (1) MY172723A (es)
PE (1) PE20141282A1 (es)
PH (2) PH12014500729A1 (es)
PL (1) PL2766361T3 (es)
PT (1) PT2766361T (es)
RS (1) RS55342B1 (es)
RU (1) RU2625315C2 (es)
SG (1) SG11201401279XA (es)
SI (1) SI2766361T1 (es)
TW (1) TWI571466B (es)
UA (1) UA115042C2 (es)
UY (1) UY34382A (es)
WO (1) WO2013055897A1 (es)
ZA (1) ZA201402556B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2015360613A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
US20170182179A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
WO2016094517A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
CN104473923B (zh) * 2014-12-29 2016-08-17 巩春智 一种防治慢性心力衰竭的药物组合物及其应用
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
PH12022553314A1 (en) * 2016-06-08 2024-05-27 Abbvie Inc Anti-egfr antibody drug conjugates
MX2018015272A (es) * 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EP3468598A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
MX2018015268A (es) * 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
JP2019521114A (ja) * 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
TW202304996A (zh) * 2016-06-08 2023-02-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
CN109562190A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
WO2018092064A1 (en) * 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
AR119494A1 (es) * 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
IL303048A (en) 2020-11-24 2023-07-01 Novartis Ag Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
US20240238423A9 (en) * 2022-05-06 2024-07-18 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
EP4519272A1 (en) * 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CA3256012A1 (en) 2022-05-20 2023-11-23 Les Laboratoires Servier ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
JP2025517435A (ja) 2022-05-20 2025-06-05 ノバルティス アーゲー 抗新生物薬化合物の抗体－薬物コンジュゲートおよびその使用の方法
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗ｃｄ７抗體藥物結合物及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CA2413086C (en) * 2000-06-21 2011-06-28 Alexander Alanine Benzothiazole derivatives
CA2508947A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
AU2008242703B2 (en) 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
AU2009335843A1 (en) * 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
US8114893B2 (en) * 2008-12-19 2012-02-14 Genentech, Inc. Compounds and methods of use
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
ME02514B (me) 2017-02-20
DOP2019000022A (es) 2019-02-15
CL2014000905A1 (es) 2014-09-22
MY172723A (en) 2019-12-11
UY34382A (es) 2013-05-31
CR20140205A (es) 2014-07-17
ECSP14000357A (es) 2015-11-30
JP6155270B2 (ja) 2017-06-28
EP2766361A1 (en) 2014-08-20
AU2012322698A1 (en) 2014-04-17
EP2766361B1 (en) 2016-08-10
AR088327A1 (es) 2014-05-28
PL2766361T3 (pl) 2017-03-31
HK1200167A1 (zh) 2015-07-31
TWI571466B (zh) 2017-02-21
PH12014500729A1 (en) 2014-05-12
JP6395893B2 (ja) 2018-09-26
CA2851364A1 (en) 2013-04-18
SG11201401279XA (en) 2014-05-29
PH12015501498A1 (en) 2015-12-14
MX2014004556A (es) 2014-07-09
JP2014530238A (ja) 2014-11-17
CY1118224T1 (el) 2017-06-28
PT2766361T (pt) 2016-10-27
IL231856A (en) 2017-07-31
ZA201402556B (en) 2017-09-27
KR20140075793A (ko) 2014-06-19
ES2598877T3 (es) 2017-01-30
TW201319064A (zh) 2013-05-16
CA2851364C (en) 2020-03-10
AU2017206246B2 (en) 2018-07-26
MX356031B (es) 2018-05-09
WO2013055897A1 (en) 2013-04-18
BR112014009053B1 (pt) 2022-03-29
BR112014009053A2 (pt) 2017-06-13
RS55342B1 (sr) 2017-03-31
PH12015501498B1 (en) 2018-03-14
AU2017206246A1 (en) 2017-08-10
LT2766361T (lt) 2016-11-10
SI2766361T1 (sl) 2016-11-30
HRP20161319T1 (hr) 2016-12-16
HUE030589T2 (en) 2017-05-29
RU2625315C2 (ru) 2017-07-13
JP2017197530A (ja) 2017-11-02
IL231856A0 (en) 2014-05-28
DOP2014000070A (es) 2014-07-31
DK2766361T3 (en) 2016-12-05
RU2014119250A (ru) 2015-11-20
NZ623100A (en) 2016-04-29
KR102019643B1 (ko) 2019-09-10
CR20200097A (es) 2020-03-31
CO6950476A2 (es) 2014-05-20
GT201400064A (es) 2014-12-23
UA115042C2 (uk) 2017-09-11

Similar Documents

Publication Publication Date Title
PE20141282A1 (es) Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2015000908A (es) Pirimidinas fusionadas como inhibidores del complejo p97.
MX377305B (es) DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
CO6821946A2 (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tramiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
MY189363A (en) Mnk inhibitors and methods related thereto
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
MX2014001665A (es) Derivado heterociclico y farmaceutico.
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
PE20141202A1 (es) Compuesto de ciclopropanoamina
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
EA201692465A1 (ru) Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида
PE20141351A1 (es) Triazolopiridinas
JP2016504400A5 (es)
DOP2016000266A (es) CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS

Legal Events

Date Code Title Description
FG Grant, registration